Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100791 | 0.90 | NTRK1 (0.43) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21625424 | 0.90 | NTRK1 (0.43) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21625426 | 0.90 | NTRK1 (0.43) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21637241 | 0.89 | NTRK1 (0.47) | NTRK1 | |
| SCHEMBL21625430 | 0.89 | NTRK1 (0.44) | NTRK1 | |
| SCHEMBL29894189 | 0.89 | NTRK1 (0.47) | NTRK1 | |
| SCHEMBL29894259 | 0.89 | NTRK1 (0.44) | NTRK1 | |
| SCHEMBL21625429 | 0.88 | NTRK1 (0.46) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21625427 | 0.88 | NTRK1 (0.46) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21625434 | 0.88 | NTRK1 (0.46) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277008-A1 | IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| WO-2021148807-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| WO-2020016594-A1 | IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277008-A1 | IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS TRK INHIBITORS | MUSK, TPM3, NTRK1 | NTRK1 3/4885NTRK3 5/4885NTRK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.